An update on one-dose HPV vaccine studies, immunobridging and humoral immune responses - A meeting report.

The 12th HPV Prevention and Control meeting was held on June 2-3, 2022, in Antwerp, Belgium. This technical meeting focused on several topics. This report summarises the discussions and lessons learned on two topics: an update on one-dose HPV vaccination studies and humoral immune responses upon HPV vaccination. Long-term follow-up studies from Costa Rica (eleven years) and India (ten years) report stable levels of antibodies after a single HPV vaccination. High vaccine effectiveness against incident persistent HPV 16/18 infection was seen in India (95.4%, 85.0-99.9) ten years postvaccination and in Kenya (97.5%, 81.7-99.7) eighteen months postvaccination, an important observation in a setting with a higher HPV prevalence. The potential impact of HPV vaccination using a one-dose schedule in India was modelled and showed that implementation of one-dose schedule can contribute towards achieving WHO Cervical Cancer elimination goals. These data support the WHO SAGE recommendations for adopting a one-dose schedule for females aged 9-20 years. Immunobridging studies were discussed during the meeting. General agreement was reached that when thoughtfully applied, they can support and accelerate the expanded use of HPV vaccine with new vaccine schedules, age cohorts, or vaccine formulations. Internationally standardised measurements of HPV immune responses important for the progress of HPV vaccinology field. Humoral immune responses upon HPV vaccination plateau at 24 months regardless of number of doses, therefore, data should be analysed after at least 24 months of follow-up to bridge studies accurately.

Informations de copyright

© 2023 Published by Elsevier Inc.

Déclaration de conflit d'intérêts

9AV University of Antwerp obtained unrestricted educational grants from GSK, Merck, Roche and Hologic; an investigator-initiated grant from Merck and speaker fees from Merck. MB received medical writing fees from Merck, SPMSD and GSK. DWJ received funding from GSK Biologicals for a clinical trial of HPV vaccine and donation of Gardasil® from Merck and Co. MS is part of the Global Advisory Board HPV vaccines MSD Merck. For the authors identified as personnel of the IARC or WHO, the authors alone are responsible for the views expressed in this Article, and they do not necessarily represent the decisions, policies, or views of the IARC or WHO. The designations used and the presentation of the material in this Article do not imply the expression of any opinion whatsoever on the part of WHO and the IARC about the legal status of any country, territory, city, or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries.The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.